Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 6/20 | 0.35 |
| ▸ | CTSK | P43235 | 6/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9974287 | 0.86 | KCNH2 (0.47) | KCNH2CTSSCTSKNOS1NOS2 | |
| SCHEMBL9974291 | 0.83 | KCNH2 (0.44) | KCNH2CTSSCTSKNOS1NOS2 | |
| SCHEMBL10120823 | 0.83 | SYK (0.39) | KCNH2NOS1NOS2 | |
| SCHEMBL2522650 | 0.79 | KCNH2 (0.67) | KCNH2CTSSCTSKNOS1NOS2 | |
| SCHEMBL23006785 | 0.78 | IRAK4 (0.38) | KCNH2NOS1NOS2CXCR4 | |
| SCHEMBL19085083 | 0.78 | CCR1 (0.39) | CXCR4 | |
| SCHEMBL8250521 | 0.76 | KCNH2 (0.58) | KCNH2NOS1NOS2 | |
| SCHEMBL13833509 | 0.75 | CCR1 (0.46) | NOS2KDM4EALDH1A1HPGDCXCR4 | |
| SCHEMBL427622 | 0.75 | KCNH2 (0.52) | KCNH2CTSSCTSKNOS1NOS2 | |
| SCHEMBL22299565 | 0.75 | CCR1 (0.46) | NOS2KDM4EALDH1A1HPGDCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, NSUN2 | KCNH2 2968/4885CTSS 721/4885CTSK 1560/4885 |
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | NSUN2, HCCS, HAVCR2 | KCNH2 3034/4885CTSS 695/4885CTSK 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.